Chinese Journal of Tissue Engineering Research ›› 2019, Vol. 23 ›› Issue (25): 4050-4055.doi: 10.3969/j.issn.2095-4344.1792

Previous Articles     Next Articles

Effect of human amniotic mesenchymal stem cell transplantation on airway goblet cell proliferation and mucin 5ac expression in asthmatic mice

Yang Hongxia, Shi Qinghong, Weng Minhua, Zhang Jianyong, Zhao Jianjun, Chen Ling
  

  1. Second Department of Pulmonary and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou Province, China
  • Revised:2019-03-25 Online:2019-09-08 Published:2019-09-08
  • Contact: Zhang Jianyong, MD, Chief physician, Second Department of Pulmonary and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou Province, China
  • About author:Yang Hongxia, Master, Attending physician, Second Department of Pulmonary and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou Province, China
  • Supported by:

    the Scientific and Technological Fund Project of Guizhou Province, No. [2013]2329 (to YHX); the Scientific and Technological Plan Subject of Guizhou Province, No. [2015]3050 (to ZJJ)

PDF

141

Abstract:

BACKGROUND: Our preliminary studies indicated that human amniotic mesenchymal stem cells transplantation can reduce airway inflammatory responses in asthmatic mice, but the effect of human amniotic mesenchymal stem cells on airway mucus hypersecretion is unclear.
OBJECTIVE: To investigate the effect of human amniotic mesenchymal stem cells transplantation on airway goblet cell proliferation and mucin 5ac expression in asthmatic mice.
METHODS: Twenty-eight BALB/C mice were randomly divided into sham operation group (sensitized with normal saline at the 1st and 13th days, and motivated with nebulized normal saline at the 19th to 23th days), model group (sensitized with egg albumin and motivated with nebulized egg albumin to construct a mouse model of asthma), experimental group (transplanted with human amniotic mesenchymal stem cells via the tail vein of the mouse model of asthma at the 18th day), and blank group (sensitized with normal saline, motivated with nebulized normal saline, and transplanted with human amniotic mesenchymal stem cells via the tail vein at the 18th day). There were seven mice in each group. All the mice were sacrificed at the 24th day. We observed the pathological changes in the airway and the proliferation of epithelial goblet cells in each group. We detected the expression of interleukin-5 in the bronchoalveolar lavage fluid and the mRNA and protein levels of mucin 5ac in the lung tissue.
RESULTS AND CONCLUSION: (1) In the model group, there were a large amount of inflammatory cells infiltrated in the bronchus, perivascular and lung interstitial tissues; the goblet cells of the airway epithelium proliferated obviously, the tracheal wall was thickened to varying degrees, and there were a large amount of mucus secretion in some lumens with the lumen being narrow or even occluded. In the experimental group, airway inflammatory cell infiltration and goblet cell hyperplasia were alleviated. (2) Compared with the sham operation and blank groups, the model group showed increases in the proportion of airway epithelial goblet cells, number of goblet cells, interleukin-5 level in the bronchoalveolar lavage fluid, and expression of mucin 5ac protein and mRNA in the airway (P < 0.01). Compared with the model group, the above-mentioned indexes of the experimental group were significantly decreased (P < 0.01). All the findings indicate that transplantation of human amniotic mesenchymal stem cells can inhibit airway inflammatory response and epithelial goblet cell proliferation, downregulate mucin 5ac expression, and alleviate airway mucus hypersecretion.

Key words: human amniotic mesenchymal stem cells, asthma, goblet cells, interleukin-5, mucin 5ac, airway inflammatory response, airway mucus hypersecretion

CLC Number: